8月6日上午，晶泰控股（02228.HK）股价盘中大涨15.91%，引发市场广泛关注。
消息面上，晶泰控股于8月5日晚间宣布，公司与DoveTree完成总订单规模约470亿港元（59.9亿美元）的管线合作签约，并已收到协议约定的首付款约4亿港元（5100万美元）。根据协议，晶泰控股将利用其基于"AI+机器人"的人工智能药物发现平台，为DoveTree开发多个针对肿瘤学、免疫及炎症疾病、神经系统疾病及代谢失调领域的靶点药物。作为回报，除首付款外，晶泰控股还有权获得约3.85亿港元的进一步付款，以及高达约462亿港元的潜在里程碑付款及销售分成。
分析人士认为，此次合作创下人工智能新药研发领域订单规模的新纪录，不仅印证了晶泰控股在AI驱动药物研发领域的领先技术实力，也显示了全球生物医药产业对智能化药物发现模式的高度认可。这笔大额订单有望显著提升晶泰控股的营收和盈利能力，推动公司加快实现盈利。投资者对晶泰控股未来发展前景的信心明显增强，推动其股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.